Evidence mapPaperPMID 27600795Full record

Trial reportJournal of atherosclerosis and thrombosis2017

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients.

Ta-Chen Su, Juey-Jen Hwang, Kuo-Chin Huang, Fu-Tien Chiang, Kuo-Liong Chien, Kuo-Yang Wang, Min-Ji Charng, Wei-Chuan Tsai, Lian-Yu Lin, Runar Vige and 2 more

Registry-linked trialOpen access · diamondAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of atherosclerosis and thrombosis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03216057 (Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. A Randomized, Double Blind, Placebo-controlled Clinical Trial.), which is not on this map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03216057 nacompletednot on this map

Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. A Randomized, Double Blind, Placebo-controlled Clinical Trial.

TypeinterventionalSponsorHospital Infantil de Mexico Federico GomezRan2008 to 2016Enrolled168ConditionsHypertriglyceridemia, Pediatric ObesityArmsOmega-3 fatty acid 3 grams per day, Placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Ta-Chen SuDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital.
Juey-Jen Hwang
Kuo-Chin Huang
Fu-Tien Chiang
Kuo-Liong Chien
Kuo-Yang Wang
Min-Ji Charng
Wei-Chuan Tsai
Lian-Yu Lin
Runar Vige
José Emilio Ruiz Olivar
Chuen-Den Tseng
National Taiwan University Hospital · TWFerrer Grupo (Spain) · ESNational Cheng Kung University Hospital · TWNational Taiwan University · TWTaichung Veterans General Hospital · TWTaipei Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimInformation regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the efficacy and safety of Omacor

methodsA multicenter, randomized, double-blind, placebo-controlled, parallel study in adults with hypertriglyceridemia was conducted. After a five-week diet lead in period patients with triglycerides =200-1000 mg/dL were randomized to receive Omacor

resultsA total of 253 Taiwanese patients were randomized, of which 65.6% (166) were men. At the end of the treatment, the percentage change in triglyceride serum levels in both the Omacor

conclusionsOmacor

Indexed as

Dietary SupplementsAdultDocosahexaenoic AcidsDouble-Blind MethodDrug CombinationsEicosapentaenoic AcidFatty Acids, Omega-3FemaleHumansHypertriglyceridemiaHypolipidemic AgentsLife StyleMaleMiddle AgedSafetySeverity of Illness IndexDocosahexaenoic AcidsDrug CombinationsEicosapentaenoic AcidFatty Acids, Omega-3Hypolipidemic AgentsOmacorTriglycerides

Identifiers

PMID27600795
PMCPMC5383544
OpenAlexW2517463619

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.